Wednesday , June 28 2017
Breaking News
Home / Business / Lupin gets six observations from USFDA for Indore plant: Report

Lupin gets six observations from USFDA for Indore plant: Report

Lupin has reportedly received 6 USFDA Form 483 observations for its Indore plant. The facility was inspected by the US drug regulator between May 8 and May 19, 2017. Earlier, USFDA has issued eight observations for the company’s Aurangabad unit, which was inspected between April 17 and 26, 2017.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

About editor